NAT2 and tuberculosis: In Japan, Higuchi et al. (Higuchi et al., 2007) found that slow acetylation genotype NAT2*6 could increase hepatotoxicity in patients with TB, while acetylation genotype NAT2*4/*4 could reduce the risk of liver injury in such patients.